|
Refractory Cytopenia of Childhood
|
0.100 |
Biomarker
|
disease |
BEFREE |
Agents targeting the vascular endothelial growth factor (VEGF) and its receptors (VEGFRs), as well as the mammalian target of rapamycin (mTOR) and immune checkpoint receptor programmed death 1 (PD-1) signaling pathway have improved clinical outcomes for patients with advanced renal cell carcinoma (RCC).
|
30158285 |
2019 |
|
Refractory Cytopenia of Childhood
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Advanced renal cell carcinoma (RCC) is commonly treated with vascular endothelial growth factor or mammalian target of rapamycin inhibitors.
|
31465470 |
2019 |
|
Refractory Cytopenia of Childhood
|
0.100 |
Biomarker
|
disease |
BEFREE |
Also included is the utilization of mTOR inhibitors in both advanced renal cell carcinoma (RCC) and in patients with tuberous sclerosis complex (TSC) associated angiomyolipoma (AML).
|
31080770 |
2019 |
|
Refractory Cytopenia of Childhood
|
0.100 |
Biomarker
|
disease |
BEFREE |
The treatment landscape in advanced and metastatic renal cell carcinoma (RCC) is moving from the inhibition of tyrosine kinases (TKI) and the mammalian target of rapamycin (mTOR) inhibitors to specific immunooncology agents like immune checkpoint inhibitors (ICI).
|
29120911 |
2018 |
|
Refractory Cytopenia of Childhood
|
0.100 |
Biomarker
|
disease |
BEFREE |
Currently, targeted therapies including vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors are widely used in the treatment of metastatic RCC.
|
29323560 |
2018 |
|
Refractory Cytopenia of Childhood
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, to explain possible mechanisms of action of mTOR inhibitors in this type of RCC.
|
29702156 |
2018 |
|
Refractory Cytopenia of Childhood
|
0.100 |
Biomarker
|
disease |
BEFREE |
The acceleration of glucose accumulation dependent on mTOR in RCC assessed by FDG PET/CT demonstrated acquisition of resistance to TKI.
|
28068944 |
2017 |
|
Refractory Cytopenia of Childhood
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tivozanib (Fotivda<sup>®</sup>) is an oral, potent and highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor that has been approved in the EU, Iceland and Norway for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mammalian target of rapamycin (mTOR) pathway inhibitor-naive following disease progression after one prior treatment with cytokine therapy for advanced RCC.
|
28971328 |
2017 |
|
Refractory Cytopenia of Childhood
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report the largest retrospective cohort of patients with mChRCC treated with TT and no significant difference between AA and mTOR inhibitors was observed for TTF and OS.
|
28549248 |
2017 |
|
Refractory Cytopenia of Childhood
|
0.100 |
Biomarker
|
disease |
BEFREE |
The combination of lenvatinib, a multiple receptor tyrosine kinase inhibitor, plus everolimus, a mammalian target of rapamycin (mTOR) inhibitor, significantly improved clinical outcomes versus everolimus monotherapy in a phase II clinical study of metastatic renal cell carcinoma (RCC).
|
28107584 |
2017 |
|
Refractory Cytopenia of Childhood
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Metastatic renal cell carcinoma (RCC) patients are commonly treated with vascular endothelial growth factor (VEGF) inhibitors or mammalian target of rapamycin inhibitors.
|
27751729 |
2017 |
|
Refractory Cytopenia of Childhood
|
0.100 |
Biomarker
|
disease |
BEFREE |
It has recently been approved by the European Medicines Agency (EMA) for first-line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mammalian target of rapamycin (mTOR) pathway inhibitor-naive, following disease progression after one prior treatment with cytokine therapy for advanced RCC.
|
29451277 |
2017 |
|
Refractory Cytopenia of Childhood
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we discuss the preclinical and clinical experience with the rapalogues in RCC, potential mechanisms of resistance to the rapalogues, and the progress in the clinical development of novel agents directed against the phosphatidylinositol 3-kinase/Akt/mTOR pathway.
|
23867512 |
2014 |
|
Refractory Cytopenia of Childhood
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patient selection may be improved by mTOR immunostaining of primary RCC.
|
20830770 |
2011 |
|
Refractory Cytopenia of Childhood
|
0.100 |
Biomarker
|
disease |
BEFREE |
There has been a recent expansion of therapeutic options in metastatic renal cell carcinoma (RCC) targeted at the vascular endothelial growth factor and mammalian target of rapamycin pathways, which are fundamental to the biology of RCC.
|
19470934 |
2009 |
|
Refractory Cytopenia of Childhood
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated the influence of the receptor tyrosine kinase inhibitor AEE788, applied alone or combined with the mammalian target of rapamycin (mTOR) inhibitor RAD001, on RCC cell adhesion and proliferation in vitro.
|
19473483 |
2009 |